IL13Rα2 CAR-T Cells Secreting Anti-PD-L1 Antibody therapy (Emergency General Hospital)

N/A

Report date: 2026/05/02 20:00:18

Base Information

Drug NameIL13Rα2 CAR-T Cells Secreting Anti-PD-L1 Antibody therapy (Emergency General Hospital)

Drug Alias NameN/A

ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy

Mechanisms of ActionInterleukin-13 receptor subunit alpha-2 modulatorsT lymphocyte replacements

TargetsInterleukin-13 receptor subunit alpha-2

Therapy Area/IndicationsGlioma

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryMainland China

CombinationsNo

Global Highest StatusPhase 1 Clinical

Highest Status in ChinaPhase 1 Clinical

Originator CompaniesEmergency General Hospital, Department of Neurosurgery

China Registration ClassN/A

Develop Information

Active CompaniesEmergency General Hospital, Department of Neurosurgery

Inactive CompaniesN/A

Active IndicationsGlioma

Inactive IndicationsN/A

Other Information

ATC CodeN/A